New Low - Stock Screener

Market Cap	87.90B	EPS (ttm)	-3.10
P/E	-	EPS this Y	-92.51%
Forward P/E	6.25	EPS next Y	1133.30%
PEG	-	EPS past 5Y	5.14%
P/S	1.93	EPS next 5Y	-4.45%
P/B	5.33	EPS Q/Q	-650.00%
Dividend	5.56%	Sales Q/Q	4.66%
Insider Own	0.08%	Inst Own	78.84%
Insider Trans	0.84%	Inst Trans	-0.74%
Short Float	1.38%	Earnings	Apr 25/b
Analyst Recom	2.64	Target Price	52.76
Avg Volume	15.34M	52W Range	43.33 - 67.16

May-16-24 10:26AM	New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis (Business Wire)
07:15AM	7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs (InvestorPlace)
May-15-24 08:57PM	Bristol Myers Squibbs CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma (Business Wire)
07:00AM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results (GlobeNewswire)
May-14-24 06:46AM	Dividend Capture Captains: The 3 Best Blue-Chip Stocks for Tactical Traders (InvestorPlace)
May-13-24 12:41PM	One stock is dragging down the S&P 500's earnings growth (Yahoo Finance)
May-10-24 04:55PM	Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint (The Wall Street Journal)
04:30PM	Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial (Business Wire)
May-09-24 03:38PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 07:00AM	Immunocore reports first quarter financial results and provides a business update (GlobeNewswire)

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Apr 01 '24	Option Exercise	3,306	6,532	Apr 02 06:45 PM
Caforio Giovanni	Executive Chair of the Board	Mar 10 '24	Option Exercise	190,130	529,662	Mar 12 05:42 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10 '24	Option Exercise	64,326	225,111	Mar 12 05:43 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Mar 10 '24	Option Exercise	54,638	129,769	Mar 12 07:58 PM
Gallman Cari	EVP, Corporate Affairs	Mar 10 '24	Option Exercise	2,761	2,655	Mar 12 08:00 PM

1⋯8 9 10 11 12 13

Upgrade your FINVIZ experience